By Will Boggs MD

NEW YORK (Reuters Health) - Cardiovascular disease and mortality rates are lower in patients with type 2 diabetes who start taking sodium-glucose co-transporter-2 (SGLT2) inhibitors instead of other glucose-lowering drugs, according to results from the CVD-REAL Nordic study.

READ MORE

News

By Will Boggs MD

NEW YORK (Reuters Health) - Cardiovascular disease and mortality rates are lower in patients with type 2 diabetes who start taking sodium-glucose co-transporter-2 (SGLT2) inhibitors instead of other glucose-lowering drugs, according to results from the CVD-REAL Nordic study.

READ MORE

The American College of Cardiology issued a decision pathway to for the selection, treatment, and follow-up care of patients with aortic stenosis.

READ MORE